# Danaher Corporation account plan

> Danaher is a life sciences and diagnostics group of more than 15 operating companies, with $24,568 million of 2025 sales and about 60,000 associates.

## At a glance

Danaher is a global life sciences and diagnostics group made up of more than 15 operating companies, including Cytiva, Pall, Beckman Coulter, Cepheid, Leica, SCIEX, IDT, Abcam and, since June 2026, Masimo. It sells mostly on a recurring basis and mostly direct, to pharma and biopharma companies, CDMOs, research institutions, hospitals and laboratories, with facilities in approximately 50 countries. In 2025 sales were $24,568 million (core +2.0%), of which recurring revenue was $20,127 million, and net earnings from continuing operations were approximately $3.6 billion ($5.03 per diluted share). Approximately 59% of 2025 sales came from outside the United States, and the group had approximately 60,000 associates at December 31, 2025. It runs on the Danaher Business System (DBS) of continuous improvement.

## Business units

- **Diagnostics** (about 40% of 2025 sales ($9,941 million)): Molecular diagnostics (Cepheid) and clinical diagnostics: clinical lab, acute care (Radiometer) and pathology (Leica Biosystems), sold to hospitals, reference laboratories and physicians' offices. 2025 core sales rose 1.5% with a 26.7% operating margin, while China's volume-based procurement cut prices; Masimo joined the segment in June 2026.
- **Life Sciences** (about 30% of 2025 sales ($7,334 million)): Instruments (flow cytometry, lab automation, mass spectrometry, microscopy), genomic and protein consumables (IDT, Aldevron, Abcam) and Pall industrial filtration. 2025 core sales fell 1.5% and margin was 7.1% after a $432 million trade-name impairment; Q2 2026 core sales rose 5.5%, its strongest quarter in several years.
- **Biotechnology** (about 30% of 2025 sales ($7,293 million)): Cytiva and Pall bioprocessing (cell culture media, chromatography resins, filtration, single-use hardware, full manufacturing suites) plus discovery and medical products, sold to pharma, biotech and CDMO customers. 2025 core sales rose 6.5% with a 25.6% operating margin, led by bioprocessing consumables.

## Strategic priorities

- **Danaher Business System**: DBS, organised in Growth, Lean, Leadership and Fundamentals pillars, is the first of three strategic priorities, alongside portfolio building through capital allocation and talent; the new CEO aims to leverage it more effectively for more consistent growth.
- **M&A-led portfolio building**: Masimo was acquired on June 10, 2026 for approximately $9.8 billion net of cash, and Leica Biosystems agreed to buy StatLab (approximately $250 million 2025 revenue), expected to close by end-2026; management says its bias to capital deployment is M&A in any of the three segments.
- **Bioprocessing capex cycle**: Management sees a multi-year capex cycle in bioprocessing equipment from brownfield expansion and reshoring, with equipment orders up more than 30% in Q1 2026 and long-term high-single-digit growth expected for bioprocessing.
- **AI and autonomous science**: Danaher treats AI as a growth accelerator for pharma and biotech, driving near-term demand for automation, instruments and reagents; Beckman Coulter Life Sciences partnered with Automata on AI-ready lab automation.
- **Masimo integration**: Targets of $125 million of cost synergies by year 5, about $50 million of revenue synergies and high-single-digit ROIC by the fifth year.
- **2026 guidance**: Full-year core growth of 3% to 4% and adjusted EPS raised to $8.45 to $8.60, with a mid-single-digit core exit rate in Q4.

## Latest results

In Q2 2026 (quarter ended June 26, 2026) sales were $6,265 million, up 5.5% reported and 3.0% core, or 4.5% core excluding respiratory testing. Net earnings were $870 million ($1.23 per diluted share) versus $555 million a year earlier, when a $432 million impairment was booked; adjusted EPS was $1.94. High-growth markets grew 15% and were approximately 31% of sales, while developed-market core sales fell slightly. Masimo-related charges cut Q2 operating margin by 175 basis points. For Q3 the company guided core revenue growth of about 2% to 3%, and full-year 2026 adjusted EPS of $8.45 to $8.60.

## Investments and deals

- **Masimo acquisition**: Closed June 10, 2026 for approximately $9.8 billion net of cash ($180.00 per share); Masimo had approximately $1.5 billion of 2025 revenue and sits in Diagnostics, financed with cash, long-term debt and commercial paper.
- **StatLab acquisition**: Leica Biosystems agreed to acquire StatLab, a histology consumables maker with approximately $250 million of 2025 revenue and more than 85% recurring revenue, expected to close by end-2026.
- **Capital expenditure**: Capex was approximately $1.2 billion in 2025 for manufacturing capacity, leased instruments, buildings, new products and IT; Pall has a new plant in startup in Singapore.
- **Share repurchases**: $3,088 million of buybacks in 2025 and $894 million in the first half of 2026.

## Challenges and risks

- **China volume-based procurement**: China (approximately 11% of sales) cut Diagnostics prices, with a policy headwind of $75 million to $100 million expected in 2026.
- **Respiratory testing decline**: Cepheid respiratory revenue fell approximately 25% in Q1 2026 on a light season; full-year respiratory revenue is expected at about 1.6 billion.
- **Bioprocessing shipment timing**: Large chromatography resin shipments moved out of 2026 at customer request, a shift of a little bit north of $100 million into 2027.
- **Research funding and policy**: Lower funding at emerging biotech, academic and government customers weighed on Life Sciences; academic and government demand remains muted overall.
- **Debt and tariffs**: Total debt rose to approximately $18.4 billion at end-2025 before the Masimo financing; tariff outcomes remain uncertain after the IEEPA ruling, and the Middle East conflict raised logistics costs.

## What leadership says

> "accelerate innovation, enhance our business capabilities, and more effectively leverage the Danaher Business System" — Julie Sawyer Montgomery, President and CEO (from October 1, 2026), Press release on her appointment, August 3, 2026

> "We are at a uniquely opportune moment for Danaher, with untapped potential to accelerate growth across the enterprise." — Steven Rales, Chairman, Press release on the CEO appointment, August 3, 2026

> "we're in the early innings here of a multi-year capex cycle" — Rainer Blair, President and CEO (then), Q2 2026 earnings call, July 21, 2026

> "we think AI is going to be a growth accelerator for the pharma and biotech industry" — Rainer Blair, President and CEO (then), Q1 2026 earnings call, April 21, 2026


## Where a supplier can help

- **Masimo and StatLab integration**: Integrating Masimo against $125 million of cost synergies and closing StatLab create work for integration, IT, procurement and commercial-enablement suppliers.
- **Bioprocessing capacity build-out**: The multi-year bioprocessing capex cycle and new plants such as Pall's in Singapore point to engineering, automation and construction partners.
- **AI and lab automation**: The AI and autonomous-science priority opens doors for data, software and automation vendors working with Beckman and the Life Sciences businesses.
- **Commercial capability under a new CEO**: Julie Sawyer Montgomery's agenda to enhance business capabilities and leverage DBS more effectively suits sales-enablement, operations and process-improvement providers.
- **Supply chain and logistics**: Tariff uncertainty and higher Middle East logistics costs suggest sourcing and logistics optimisation offers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/313616/000031361626000062/dhr-20251231.htm)

Annual report · 2026-02-24

- Danaher is a global life sciences and diagnostics group of more than 15 operating companies organised in three segments (Biotechnology, Life Sciences, Diagnostics), with facilities in approximately 50 countries and approximately 60,000 associates at December 31, 2025.
- 2025 sales were $24,568 million (+3.0% reported, +2.0% core); net earnings from continuing operations were approximately $3.6 billion, or $5.03 per diluted share, versus $5.29 in 2024; operating margin fell to 19.1% from 20.4%, 120 basis points of it from intangible asset impairments.
- Segment sales 2025: Diagnostics $9,941 million (26.7% operating margin), Life Sciences $7,334 million (7.1% margin after a $432 million genomics trade-name impairment), Biotechnology $7,293 million (25.6% margin, core sales +6.5% led by bioprocessing consumables).
- Recurring revenue was $20,127 million of the $24,568 million; approximately 59% of sales came from outside the United States, high-growth markets were approximately 29% of sales, and China approximately 11%.
- Headwinds: China's volume-based procurement and reimbursement changes cut Diagnostics prices 1.0%; lower funding at emerging biotech, academic and government customers hit Life Sciences; incremental 2025 tariff costs were less than $300 million and largely offset.
- Strategy rests on the Danaher Business System (DBS), portfolio building through acquisitions, and talent; on February 16, 2026 Danaher agreed to buy Masimo (pulse oximetry and patient monitoring, approximately $1.5 billion 2025 revenue) for approximately $9.9 billion, to sit in Diagnostics.
- Cash: operating cash flow $6,416 million, capex approximately $1.2 billion, share repurchases $3,088 million, dividends $878 million; total debt approximately $18.4 billion and cash approximately $4.6 billion at year end.
- 2026 assumptions in the filing: Bioprocessing growth similar to 2025, a modest improvement in Life Sciences end markets, and higher Diagnostics growth as China policy headwinds pass their peak.

### [Quarterly Report on Form 10-Q for Q2 2026](https://www.sec.gov/Archives/edgar/data/313616/000031361626000161/dhr-20260626.htm)

Interim report · 2026-07-21

- Q2 2026 (quarter ended June 26, 2026): sales $6,265 million, +5.5% reported, +3.0% core and +4.5% core excluding respiratory testing; net earnings $870 million, or $1.23 per diluted share, versus $555 million ($0.77) a year earlier, when a $432 million trade-name impairment was booked.
- First half 2026: sales $12,216 million (+4.5%, core +2.0%), net earnings approximately $1.9 billion ($2.68 per diluted share), operating cash flow approximately $2.9 billion (+8%).
- Masimo was acquired on June 10, 2026 for approximately $9.8 billion net of cash ($180.00 per share) and is now part of Diagnostics; approximately $5.0 billion of goodwill was recorded; deal-related charges cost the group 175 basis points of Q2 operating margin.
- Segments Q2: Biotechnology $1,920 million (core +2.5%, 29.0% margin), Life Sciences $1,879 million (core +5.5%, 13.0% margin), Diagnostics $2,466 million (core +2.0%, +5.0% excluding respiratory; 16.9% margin).
- High-growth markets grew 15% and were approximately 31% of Q2 sales; developed-market core sales were down slightly.
- Headwinds: a less severe respiratory season, China volume-based procurement (Diagnostics price -1.5%), large bioprocessing customers moving shipments out of the quarter, and higher logistics costs from the Middle East conflict.
- From Q3 2026 the core sales measures will exclude any tariff refunds returned to customers, after the Supreme Court ruled IEEPA does not authorise the tariffs; the company intends to pursue refunds.

### [Q2 2026 earnings call transcript](https://www.webull.com.au/news-detail/15265556131554304)

Executive talk · Rainer Blair, President and Chief Executive Officer · 2026-07-21

- Rainer Blair (President and CEO at the time) and CFO Matt Gugino, July 21, 2026: a "better-than-expected" quarter, sales $6.3 billion, core +3%, core excluding respiratory +4.5% (a 150 basis point acceleration from Q1), adjusted EPS $1.94 (up approximately 8%).
- Life Sciences had "their strongest quarter in several years" (core +5.5%); Pall applied filtration grew approximately 10% on semiconductor and memory customers, with a new plant starting up in Singapore; Abcam had its best quarter since acquisition.
- Bioprocessing grew only low-single digits as a few very large chromatography resin shipments (typically $10 to $30 million each) moved out of the year at customer request; Gugino put the shift at "a little bit north of $100 million" into 2027, while orders grew mid-teens in both consumables and equipment.
- Blair sees "the early innings here of a multi-year capex cycle" in bioprocessing equipment, from brownfield expansion and reshoring; greenfield projects are being quoted but take two or three years.
- Masimo closed in early June, ahead of plan, grew high-single digits and is expected to be immediately accretive; Leica Biosystems agreed to buy StatLab (approximately $250 million 2025 revenue, more than 85% recurring), expected to close by end-2026.
- Guidance: Q3 core revenue +2% to 3% (about 5% excluding respiratory), a mid-single digit core exit rate in Q4, full-year core +3% to 4% and adjusted EPS raised to $8.45 to $8.60; respiratory revenue about 1.6 billion for the year.
- Academic is "less than 5% of our revenues"; Beckman Life Sciences automation is benefiting from autonomous-lab and AI-enabled drug discovery investment.

### [Q1 2026 earnings call transcript](https://bullfincher.io/companies/danaher-corporation/earnings-call/fy2026-q1)

Executive talk · Rainer Blair, President and Chief Executive Officer · 2026-04-21

- Rainer Blair (President and CEO at the time) and CFO Matt Gugino, April 21, 2026: sales $6 billion, core +0.5%, with a 2.5% respiratory headwind against 3% core growth in the rest of the business; adjusted operating margin 30.2% and adjusted EPS $2.06 (+9.5%).
- Bioprocessing grew high-single digits, with notable strength in China; equipment orders grew more than 30%, "the first quarter of year-over-year equipment order growth in nearly 2 years".
- Masimo rationale: "a very typical Danaher deal", followed for over a decade, adjacent to Radiometer in acute care; targets of $125 million of cost synergies by year 5, about $50 million of revenue synergies and high-single digit ROIC by the fifth year.
- Blair calls AI "a growth accelerator for the pharma and biotech industry", raising drug pipeline yields (today "just above 10%") and creating near-term demand for automation, instruments and reagents for autonomous science; internally "AI-enabled DBS and DBS-enabled AI".
- China Diagnostics policy headwind of $75 million to $100 million in 2026 is playing out as expected; China bioprocessing grew double digits.
- Guidance kept at 3% to 6% core growth (anchored to the low end), adjusted EPS raised to $8.35 to $8.55, more than $5 billion of 2026 free cash flow expected; net debt to EBITDA about 2.5x after Masimo, leaving room for more M&A in any segment.

### [Press release: Danaher appoints Julie Sawyer Montgomery as President and CEO](https://www.sec.gov/Archives/edgar/data/313616/000119312526330652/d161342dex991.htm)

Report · 2026-08-03

- August 3, 2026: Danaher's board appointed Julie Sawyer Montgomery President and Chief Executive Officer and a board member, effective October 1, 2026; Rainer Blair retires that day and stays as senior advisor until March 31, 2027.
- Sawyer Montgomery joined in 2017 at Beckman Coulter Diagnostics, became its President in 2020 and most recently was Executive Vice President responsible for the Diagnostics platform.
- Under her, Diagnostics grew from approximately $6.0 billion of revenue in 2017 to approximately $11.0 billion, while approximately tripling operating profit; she led the Masimo acquisition and the pending StatLab acquisition.
- Chairman Steven Rales: "untapped potential to accelerate growth across the enterprise"; he credits Blair with the portfolio transformation and steering 60,000+ associates through COVID-19.
- Her stated agenda: "accelerate innovation, enhance our business capabilities, and more effectively leverage the Danaher Business System", aiming at "more consistent growth".
- Special equity incentive awards were announced for key leaders and the founders; Q3 and full-year 2026 guidance unchanged.

## Questions about Danaher Corporation

### What does Danaher do?

Danaher makes life sciences tools, bioprocessing products and diagnostics through more than 15 operating companies such as Cytiva, Pall, Beckman Coulter, Cepheid and Masimo, organised in Biotechnology, Life Sciences and Diagnostics.

### What is Danaher's revenue?

2025 sales were $24,568 million, with net earnings from continuing operations of approximately $3.6 billion; Q2 2026 sales were $6,265 million.

### How many employees does Danaher have?

Approximately 60,000 associates at December 31, 2025.

### Who is Danaher's CEO?

Julie Sawyer Montgomery became President and CEO on October 1, 2026, succeeding Rainer Blair; she previously led the Diagnostics platform.

### What is Danaher's strategy?

It rests on the Danaher Business System, portfolio building through acquisitions such as Masimo, and talent, with AI-driven lab automation and the bioprocessing capex cycle as growth themes.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
